About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Docs on Twitter


Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Apotex Corp. v. Merck & Co., Inc. (Fed. Cir. 2007) | Main | IPO President Seeks Deletion of Patent Reform Provision »

December 12, 2007

Eisai to Buy MGI PHARMA

    By Jason Derry --

Eisai Eisai Co., Ltd. and MGI PHARMA, Inc. have announced that Eisai will acquire MGI PHARMA for approximately $3.9 billion.  Eisai is a research-based company focusing on discovery, development, and marketing of therapeutic products in the fields of neuroscience, gastrointestinal disorders, and oncology.  MGI PHARMA is a biopharmaceutical company that focuses on oncology.  MGI PHARMA currently has a number of products on the market in the U.S., including Aloxi® (palonosetron hydrochloride) for injection, Mgi_pharma_2 Dacogen® (decitabine) for injection, and Gliadel® Wafer (polifeprosan 20 with carmustine implant), and also has a large pipeline of therapeutic agents in various clinical trials.  Eisai's acquisition of MGI PHARMA is in line with its strategic plan of strengthening its worldwide position in the field of oncology.

Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.

Posted at 06:55 PM in Licensing |

Comments

The comments to this entry are closed.

March 2023

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31  

Categories

Archives

More...